Gaithersburg Biotech 20/20 BioLabs Lists on Nasdaq
The Gaithersburg-based company joined the Nasdaq exchange in February 2026 under the ticker symbol AIDX.
Updated on Oct. 15, 2026 in Biotech
Live Poll
Would you use home-collection laboratory tests to screen for chronic diseases and cancer?
In February 2026, Gaithersburg firm 20/20 BioLabs successfully completed a direct listing on the Nasdaq stock market. The company, formerly known as 20/20 GeneSystems, focuses on developing home-collection laboratory tests for disease screening.
Why it matters
The company leverages existing blood test platforms and proprietary machine learning analytics to streamline the development process and enter public markets. This approach aims to reduce costs while accelerating the delivery of diagnostic tools.
20/20 BioLabs utilizes blood tests equipped with microneedle patches to collect samples from arm capillaries. The firm integrates machine learning models with existing biomarker data to enhance its screening capabilities.
The players
20/20 BioLabs
This Gaithersburg-based biotechnology company creates home-collection lab tests using microneedle technology and machine learning.
The details
Founded in 2000, 20/20 BioLabs specializes in diagnostics that combine lab technology with proprietary data analysis. The company is currently working toward securing FDA approval for its OneTest for Cancer product, which is already being utilized by Maryland fire departments through state-funded initiatives.
Timeline
20/20 BioLabs was founded as 20/20 GeneSystems in 2000.
The company obtained its direct listing on the Nasdaq in February 2026.
Maryland fire departments received state funding for cancer screenings in March 2026.
Medicare is scheduled to begin coverage for FDA-approved cancer detection tests in 2028.
The Tech Race
The company is positioning its diagnostic offerings to align with the scheduled 2028 Medicare coverage expansion for multi-cancer early detection tests. This trajectory mirrors broader industry efforts to standardize non-invasive screening technologies within the U.S. healthcare system.
For now, the company's diagnostic tests are being deployed in specific state-funded programs like those for Maryland fire departments. Once FDA approval is secured, these home-collection tools could change how individuals screen for cancer by removing the need for traditional clinic visits.
The takeaway
The move to public markets signals a scaling phase for the Gaithersburg firm as it pursues regulatory milestones. Residents should monitor future FDA announcements to see when these diagnostic technologies might become widely available for general use.
Further reading
For additional context on the local industry, visit the Biotech section.
Source note: This article includes information reported by Bethesda Magazine.
Live Poll
Would you use home-collection laboratory tests to screen for chronic diseases and cancer?
